News & Insights
Find the latest updates, news and insights from across BAP Pharma’s expert teams.
July 20, 2026
For years, Rare Disease Access has been defined by three critical questions: Does a treatment exist? Is it approved? Will it be...
July 20, 2026
Across the life sciences industry, there is growing pressure to accelerate the path from development to patient access. Faster IND approvals, streamlined...
May 18, 2026
In complex clinical trials, packaging and labelling are often treated as necessary executional steps — but secondary. In reality, they are critical...
May 15, 2026
The Challenge A leading BAP Pharma client required urgent local sourcing in China for a decentralised clinical study in immunology. The immediate...
May 14, 2026
The Challenge A critical Phase III cardiovascular trial restart was placed at immediate risk when a previous supplier failed to deliver six...
May 13, 2026
In multi-country clinical trials, labelling complexity increases rapidly. Different regulatory requirements, language variations, and country-specific interpretations all converge at a single point:...
May 6, 2026
The Ehlers-Danlos Society – Why are people with EDS and HSD receiving such late access to innovative therapies? What is Ehlers-Danlos syndrome...
March 12, 2026
Managed Access Programs are a key pillar of the drug development lifecycle, yet they remain widely misunderstood – both by the people...
February 13, 2026
How we help Biotechs save lives sooner Patients with rare diseases face all kinds of challenges in their lives, including accessing the...